Jazz Pharmaceuticals plc JAZZ
At closeNov 3, 2026, 4:03 PM EST
After hours · Nov 3, 4:03 PM ET
- YTD
- +35.14%
- 1 year
- +66.02%
- Market cap
- 14.91B
- Revenue (ttm)
- 4.60B
- Profit margin
- 20.45%
- EPS (ttm)
- 3.38
- Shares out
- 64.91M
- P/E ratio
- 67.97
- Forward P/E
- 8.94
- YTD return
- +35.14%
- 1-year return
- +66.02%
- Volume
- 1.68M
- Avg volume
- 892.51K
- Open
- 225.37
- Previous close
- 214.44
- Day's range
- 218.53 – 234.78
- 52-week range
- 128.80 – 266.38
- Beta
- 0.37
- Analysts
- Strong Buy
- Price target
- 295.77 (+28.7%)
- Earnings date
- Feb 23, 2027
2Y +120.33 (+109.98%)
Key statistics
- Enterprise value
- 16.13B
- PEG ratio
- 0.96
- Price / sales
- 3.24
- Price / book
- 3.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 15.50%
- Free cash flow
- 1.43B
- Total cash
- 2.20B
- Total debt
- 4.41B
- Return on equity
- 22.11%
- Short % of float
- 9.30%
- 50-day average
- 231.16
- 200-day average
- 216.85
Analyst view
Consensus: strong buy
- Target (low)
- 225.00
- Target (mean)
- 295.77
- Target (high)
- 337.00
- Strong buy7
- Buy13
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate -2.38.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 6.52 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | -4.05 | -3.88 | +0.17 | +4.20% |
| Aug 3, 2026 | Jun 30, 2026 | 6.18 | 5.71 | -0.47 | -7.61% |
| May 5, 2026 | Mar 31, 2026 | 4.64 | 6.34 | +1.70 | +36.64% |
| Feb 24, 2026 | Dec 31, 2025 | 6.52 | 6.64 | +0.12 | +1.84% |
| Nov 5, 2025 | Sep 30, 2025 | 5.95 | 8.13 | +2.18 | +36.64% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | JP Morgan | main | Overweight | Overweight |
| Nov 3, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Nov 3, 2026 | RBC Capital | main | Outperform | Outperform |
| Nov 3, 2026 | Barclays | main | Overweight | Overweight |
| Oct 28, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 21, 2026 | Morgan Stanley | main | Overweight | Overweight |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Ireland
- Website
- jazzpharma.com
News
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences 
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310 
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $319 
JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View 
4 Biotech Stocks Seeing Unusual Options Volume Today 
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $305 
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $275 
Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript 
Jazz Pharmaceuticals Q3 Earnings Call Highlights 
Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Your note
Sign in to keep a note on JAZZ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COZADD BRUCE C | Director | Sale | Sep 30, 2026 | 345,875 |
| ENRIGHT PATRICK G. | Director | Stock Award(Grant) | Aug 4, 2026 | 22,984 |
| GALA RENEE D | Chief Executive Officer | Sale | Oct 5, 2026 | 141,394 |
| HENDERSON MARY ELIZABETH | Officer | Sale | Feb 25, 2026 | 28,728 |
| IANNONE ROBERT | Officer | Conversion of Exercise of derivative security | Aug 26, 2026 | 65,686 |
| JOHNSON PHILIP L | Chief Financial Officer | Stock Award(Grant) | Feb 25, 2026 | 62,223 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.19% | 5,968,603 | 1.37B | Jun 29, 2026 |
| FMR, LLC | 7.10% | 4,609,326 | 1.06B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.68% | 3,036,213 | 697.54M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.20% | 2,729,650 | 627.11M | Jun 29, 2026 |
| Capital World Investors | 4.16% | 2,697,610 | 619.75M | Jun 29, 2026 |
| LSV Asset Management | 3.50% | 2,275,145 | 522.69M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 2,312,286 | 531.22M | Sep 29, 2026 |
| AMERICAN FUNDS FUNDAMENTAL INVESTORS | 2.93% | 1,900,000 | 436.51M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.92% | 1,892,522 | 434.79M | Jun 29, 2026 |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund | 2.41% | 1,561,563 | 358.75M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.11% | 1,366,767 | 314.00M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.33% | 865,937 | 198.94M | Jun 29, 2026 |